Manufacturing

Catalent Sells N.J. Facility to Ardena Amid Expansion and Acquisition Plans
Management & Regulatory Catalent Sells N.J. Facility to Ardena Amid Expansion and Acquisition Plans

Catalent, a prominent contract development and manufacturing organization (CDMO), has announced the divestment of its Somerset, New Jersey, oral solids development and small-scale manufacturing facility to Ardena, a Belgian CDMO. This transaction marks Ardena's entry into the U.S. market and

Harnessing Technology for Smarter and Sustainable Pharmaceutical Packaging
Management & Regulatory Harnessing Technology for Smarter and Sustainable Pharmaceutical Packaging

The pharmaceutical packaging industry stands at the precipice of a significant transformation. With an anticipated growth from $110.55 billion in 2024 to $176.94 billion by 2032, driven by the increasing prevalence of biologics, stringent regulations, and the menace of drug counterfeiting, it is

How Is Tosoh Bioscience Leading Sustainable Biomanufacturing Innovation?
Management & Regulatory How Is Tosoh Bioscience Leading Sustainable Biomanufacturing Innovation?

The biopharmaceutical industry is undergoing a significant transformation as it seeks to develop affordable treatments for unmet medical needs. Amidst this change, manufacturers are being pushed to cut costs and implement sustainable practices. Tosoh Bioscience stands out as a leader in sustainable

GSK's Arexvy RSV Vaccine: Efficacy Insights Over Three-Year Period
Management & Regulatory GSK's Arexvy RSV Vaccine: Efficacy Insights Over Three-Year Period

The landscape of respiratory syncytial virus (RSV) vaccination has seen significant developments with GSK's Arexvy vaccine leading the charge. Dive deep into the three-year efficacy data released by GSK, and understand what it means for the future of RSV vaccination, market dynamics, and

Is Your Viral Vector Testing Strategy Meeting These 7 Critical Steps?
Management & Regulatory Is Your Viral Vector Testing Strategy Meeting These 7 Critical Steps?

The market for gene therapies is predicted to surge from $9 billion in 2023 to $23.9 billion in 2028, according to MarketsandMarkets. With such rapid growth, it has become increasingly evident that having an effective analytical testing strategy is crucial for the successful development and

How Will Simtra's $14M Expansion Revolutionize ADC Manufacturing?
Management & Regulatory How Will Simtra's $14M Expansion Revolutionize ADC Manufacturing?

In a significant move to bolster its service offerings, Simtra BioPharma Solutions has announced a $14 million investment aimed at enhancing its Antibody-Drug Conjugates (ADCs) development and manufacturing capabilities. Set to establish a new clinical suite at its Halle/Westfalen, Germany site,

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later